rag

4 items

BBC Future · 2026-05-21 2026-05-22-w2

Google's AI is being manipulated. The search giant is quietly fighting back

A journalist published one page on his personal site claiming hot-dog-eating prowess; 20 minutes later ChatGPT, Gemini, and Google AI Overviews were repeating it as fact. Google's response to a $0 attack floor against a 2.5 billion monthly-view surface was a spam-policy clarification — which is another way of saying verification infrastructure was never part of the original build. The mechanism here is identical to what's arriving in the litigation market: AI lowered the cost of generating content that systems trust, without building any corresponding layer to evaluate whether that trust is warranted. Verified-publisher authority is repricing upward not because editorial quality improved, but because AI-citability is now a distinct and defensible position from SEO. Adversarial-input regression testing follows the same logic as DeepMind's verifier corpus: the evaluation layer is where the economics are accumulating.

BBC Future 2026-05-21-3

Google's AI is being manipulated. The search giant is quietly fighting back

A BBC journalist published one page on his personal site claiming hot-dog-eating prowess; 20 minutes later ChatGPT, Gemini, and Google AI Overviews were repeating it. Google's response to a $0 attack floor against a 2.5 billion monthly-view surface: a spam-policy clarification. Two things worth pricing: verified-publisher trust premium inverts upward as AI-citability becomes a defensible moat distinct from SEO, and adversarial-input regression suites become procurement-grade table-stakes for any enterprise running RAG against external corpora.

NBC News · 2026-05-14 2026-05-15-w2

OpenEvidence: Most physicians quietly use this medical AI tool

OpenAI launched ChatGPT for Clinicians in April without licensing NEJM or JAMA. OpenEvidence has both, and the market repriced it from $1B to $12B in 15 months on the back of 65% US physician reach and 27 million April clinical encounters. The binding constraint for entering credentialed verticals was never model quality; it was licensed-data governance and the operational-regime approval that comes with it. The Deployment Company and the LF Networking pattern this week are structurally identical: the moat that holds isn't capability, it's the layer of credential, distribution, or implementation sitting above it. For frontier labs, that means the verticals with the clearest content-licensing moats (clinical, legal, financial) will reprice fastest against whoever shows up without the corpus.

NBC News 2026-05-14-2

OpenEvidence: Most physicians quietly use this medical AI tool

OpenAI launched ChatGPT for Clinicians in April without licensing NEJM or JAMA. OpenEvidence has both, hit 65% of US physicians across 27 million April clinical encounters, and got repriced from $1B to $12B in 15 months. The binding constraint for frontier labs entering credentialed verticals is content licensing, not model capability, and OpenAI just supplied the revealed-preference proof.